Tuberculous pericarditis differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 22: | Line 22: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases | ||
| | |||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations''' | ||
| | | | ||
Line 28: | Line 29: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings | ||
|- | |- | ||
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''History''' | |||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms''' | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
Line 50: | Line 52: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan=" | ! colspan="18" |Constrictive pericarditis | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 71: | Line 74: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 89: | Line 93: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 107: | Line 112: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 125: | Line 131: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 143: | Line 150: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 161: | Line 169: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]] | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 179: | Line 188: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]] | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 197: | Line 207: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 214: | Line 225: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan=" | ! colspan="18" |Restrictive cardiomyopathy | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 235: | Line 247: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 253: | Line 266: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 271: | Line 285: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 289: | Line 304: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 307: | Line 323: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 325: | Line 342: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 343: | Line 361: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 361: | Line 380: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 379: | Line 399: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 397: | Line 418: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 415: | Line 437: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 433: | Line 456: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 15:30, 28 February 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Differentiating [Disease name] from other Diseases
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
OR
As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
History | Symptoms | Physical examination | |||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||
Chest pain | Fever | Cough | Edema/Ascites | JVP | Heart/Lung sounds | Hepatosplenomegaly | Lab 1 | Lab 2 | Lab 3 | CT Scan | MRI | Echo/Sono | |||||
Constrictive pericarditis | |||||||||||||||||
Tuberculosis | |||||||||||||||||
Idiopathic/Viral | |||||||||||||||||
Post cardiac surgery | |||||||||||||||||
Post radiation | |||||||||||||||||
Connective tissue disease | |||||||||||||||||
Malignancy | |||||||||||||||||
Mesothelioma | |||||||||||||||||
Chronic renal failure | |||||||||||||||||
Asbestosis | |||||||||||||||||
Restrictive cardiomyopathy | |||||||||||||||||
Amyloidosis | |||||||||||||||||
Sarcoidosis | |||||||||||||||||
Hemochromatosis | |||||||||||||||||
Sclerodema | |||||||||||||||||
Endomyocardial fibrosis | |||||||||||||||||
Carcinoid heart disease | |||||||||||||||||
Post radiation | |||||||||||||||||
Diabetic cardiomyopathy | |||||||||||||||||
Hurler | |||||||||||||||||
Gaucher | |||||||||||||||||
Fabry | |||||||||||||||||
Wegener | |||||||||||||||||
Metastatic malignancies |